- Headquarters: Wisconsin
- Founded: 1996
- cellectar.com
Cellectar Biosciences announces the design of the multiple dose fifth cohort of its Phase I dose escalation safety trial of lead PDC compound, CLR 131, in relapse or refractory multiple myeloma
All Cohort 4 patients had heavily pretreated relapsed or refractory multiple myeloma (greater than five prior lines) and high degree of tumor burden upon entry into the trial, and the company expects to recruit similar trial subjects for Cohort 5. Despite the challenging patient population enrolled to date, 89 percent of all Phase 1 patients achieved a clinical benefit response.
No comments:
Post a Comment